StemCell Therapy

GENEVA Fifty-five participants. Almost 500 pounds of weight loss. A nearly 90 percent attendance rate.

Based on those numbers, Finger Lakes Health employees are calling their inaugural diabetes prevention program a resounding success and looking forward to the next session in September.

We had a great experience and met our expectations in every way, said Christina Ganzon, a registered dietitian at FL Healths Diabetes Care Center in Geneva. People really enjoyed the program, thought it was very beneficial and led to a healthier lifestyle.

The free 16-week program, developed by the national Centers for Disease Control and Prevention, is geared to prevent diabetes and other chronic diseases. Classes were held from January to June at the diabetes center on West North Street and FL Healths Lifecare Medical Associates practice in Seneca Falls.

Fifty-five people took part in three classes. While they were required to attend at least nine of the 16 classes, Ganzon said the average attendance was 14 out of 16 weeks an 88-percent rate.

I was a little bit nervous about the attendance, because attendance and weight loss are two data points the CDC really focuses on ... and people sometimes join things and dont always stick with it, she said. To have an average of 14 out of 16 weeks was great. We really tried to make the program active, doing a grocery store tour and a cooking demonstration.

The goal of the program is to make lifestyle changes and lose weight to prevent the onset of diabetes. Collectively, participants lost 482 pounds an average of 8.8 pounds per person.

According to the CDC, more than 9 percent of Americans (29.1 million people) are diagnosed with diabetes, and the disease has dramatically driven up health care costs. The program involves group meetings led by lifestyle coaches (registered nurses, certified diabetes educators and dietitians) in an effort to reduce the risk of Type 2 diabetes.

Other members of the FL Health team along with Ganzon are Family Nurse Practitioner Rhonda Solomon, director of the diabetes center; Cheryl Andreas, a registered nurse; and diabetes educators Pat Cochrane and Amanda Tourtellotte.

The center provides a team of medical professionals with advanced education and experience in the field of diabetes. The philosophy of the center is based on the fact that diabetes is a complex disease that requires multiple professionals working together to make sure diabetics are getting the best care.

FL Health will start the next round of classes in mid-September (see accompanying article), as CDC guidelines call for a one-year commitment by local health agencies. Ganzon said Finger Lakes Health, which includes Soldiers & Sailors Hospital in Penn Yan, is looking to start the program in Yates County this fall but the time has not yet been determined.

Ganzon added that participants during the first session had plenty of support from family and friends. Those who came to classes alone soon found comrades in the group setting.

We had couples come in together, friends that came together, she said. Other people formed connections from being in the program. They would see each other at the grocery store, stop and talk about what they were buying. Some ended up becoming walking partners and others started going to the gym together. They bonded and started supporting one another.

Read the rest here:
FL Health diabetes program a success | Geneva | fltimes.com - Finger Lakes Times

Diabetes is one of the largest health issues of the 21st century. According to estimates from the Centers for Disease Control and Prevention, roughly29 million peoplehave diabetes in the U.S. 9.3 percent of the population.

How does the U.S. compare to other nations when it comes to levels of diabetes? Usingdata from theInternational Diabetes Federationto find the countries and territories with the highest rates of diabetes in 2015 (the most recent year available), the following is a ranking of countries with the highest diabetes rates in the world.

The report from the IDF includes levels of diabetes prevalence for people aged 20 to 79, as well as the number of diabetes-related fatalities and total number of diabetes cases. The IDF prevalence figures are age-adjusted to account for different age structures in various countries. For context, also included is the average amount spent per person with diabetes for each country, as reported by the IDF. These amounts are measured in international dollars, a hypothetical currency with the same purchasing power parity of U.S. dollars in the U.S. at a given point in time.

The data from the IDF includes the prevalence of bothType 1 and Type 2 diabetes(either diagnosed or undiagnosed). Type 1 occurs when the pancreas makes insufficient insulin; Type 2, the more common variety, occurs when the body has difficulty producing and using insulin.

The ranking is dominated by small island nations, particularly in the Pacific Islands. Many countries in this region have dealt withmalnutrition and inadequate food labeling, especially as they import more processed food. Countries in the Middle East also showed reported elevated levels of diabetes. Kuwait, Saudi Arabia and Qatar all made the top 10.

Note: Ties are broken by the number of diabetes-related deaths. There are countries where certain variables are not monitored and could not be extrapolated accurately by the IDF; these were therefore left blank.

Originally posted here:
The 25 countries with the highest diabetes rates - Fremont Tribune

A new initiative between IBM and JDRF, one of the leading groups funding the fight against type 1 diabetes, will apply machine learning to troves of worldwide research data accumulated over the years with the aim of uncovering commonalities that could point to diabetes risks in children.

The partnership is meant to give type 1 diabetes a foothold in emerging precision medicine efforts, officials say, combining JDRF's global research with the computing power of IBM.

Scientists will start by examining three separate data sets, applying algorithms to help spotlight certain patterns or common factors that might identify ways to delay or prevent type 1 diabetes in kids. The analytics tools will mine genetic, familial, autoantibody and other data to arrive at a set of features that is common to all three data sets.

[Also:IBM Watson thinks it can use AI to fight opioid addiction]

The models that emerge should quantify the risk for juvenile diabetes from the combined dataset using this foundational set of features, officials say. That will enable JDRF to better identify top predictive risk factors, cluster patients based on them and explore a number of data-driven models for predicting onset.

A bit further on, the partners have eyes toward putting big data to work helping understand root causes of type 1 diabetes and hope to apply analytics to more complex datasets, such as microbiome and genomics or transcriptomics data. The hope, of course, is to eventually put the insights gleaned from these projects toward a cure.

"JDRF supports researchers all over the world, but never before have we been able to analyze their data comprehensively, in a way that can tell us why some children who are at risk get T1D and others do not," said JDRF CEO Derek Rapp in a statement. "IBM's analysis of the existing data could open the door to understanding the risk factors of T1D in a whole new way, and to one day finding a way to prevent T1D altogether."

"Nearly 40,000 new cases of type 1 diabetes will be diagnosed in the U.S. this year. And each new patient creates new records and new data points that, if leveraged, could provide additional understanding of the disease," said Jianying Hu, senior manager and program director at IBM Research's Center for Computational Health.

"The deep expertise our team has in artificial intelligence applied to healthcare data makes us uniquely positioned to help JDRF unlock the insights hidden in this massive data set and advance the field of precision medicine towards the prevention and management of diabetes," he said

Twitter:@MikeMiliardHITNEmail the writer: mike.miliard@himssmedia.com

Excerpt from:
IBM aims machine learning at type 1 diabetes with JDRF partnership - Healthcare IT News

Cutting back on sugar? So is much of the world.

The changecan be attributed to several factors, according to a new report from Rabobank,including warnings about rising obesity rates, government initiatives like soda taxes, and manufacturers commitments to reformulatingprocessed foods to lower their sugar content.

Nor are emerging markets likely to provide a robustalternative for the sugar industry. Rising incomes tend to slow the consumption ofprocessed foods, and sugar with them.

This whole movement has gone beyond the fad stage and become a trend, saidAndy Duff, a global strategist at RaboResearchand an author of the report. It does give the market a shake. Were saying its something you shouldnt dismiss.

The trend is evident at the grocery store and in the news.Snacks are getting healthier. People are drinking less soda. Processed foods once heavy on the corn syrupare being replaced with those bearingclean labels and shorter ingredients listsso artificial sweeteners arent taking sugars place.

The most important business stories of the day.

Get Bloomberg's daily newsletter.

U.S. cities from Oakland to Philadelphiahave started taxing sugar-sweetened beverages, as have countries around the world, including Mexico, where two-thirds of the adult population is obese, and Mauritius, which has a major sugar-producing industry. Companiesare trying to meet consumer demands by announcing cuts to their sugar usage, with reductions or planned reductions coming from Mars Inc., Kellogg Co., Unilever NV, and plenty more.

Rising incomes incountries where sugar consumption has been growingare changing consumer habits, moving those regions from what the report calls sugarsrapid-growth zone to the moderate-growth zone.RaboResearch concludes thatthe rate of growth of global sugar consumption in the coming 15 years is likely to be lower than the growth rate seen in the last 15 years.

Because nobody directly measures sugar consumption, Duff said,were operating against a considerable degree of uncertainty.He stressedthat sugar consumption is still expected to grow, just at a slower pace than would have been projected a decade ago.

Were not talking about a reversal here, he said, predicting insteadshort-term turbulence and lower growth in the future.

Read more:
Sugar Consumption Is Slowing Amid Obesity and Diabetes ... - Bloomberg

During my nurse residency program, I listened to a lecture about diabetes and what people with the disease live with every day. Only months later, I was diagnosed with Type 1 diabetes.

At first I was devastated, but quickly realized I was not alone. About one in seven U.S. adults have diabetes, and California has the most new cases annually of any state. Diabetes is a chronic condition, so meticulous monitoring and management of blood-sugar levels is the key to avoiding complications. In the first year after my diagnosis, it was hard to get my levels just right. Thats when I turned to a continuous glucose monitoring system, which uses alarms and alerts when blood glucose reaches a life-threatening level.

But tens of thousands of Californians with diabetes senior citizens, low-income individuals, and people with disabilities cannot access these life-saving devices because while they are covered by health insurance for people like me, they arent covered by Medi-Cal.

Assembly Bill 447, which is making its way through the Legislature, would require Medi-Cal to cover continuous glucose monitors. AB 447 would not only help improve the lives of Medi-Cal patients, but also would help lower health care spending and save taxpayer money.

Health care costs for people with diabetes is 2.3 times higher than for those without, and a UCLA study found that 75 percent of hospital costs for patients with diabetes is paid by taxpayers. Patients without the glucose monitors are more likely to experience complications such as stroke, kidney disease, amputations and blindness. If AB 447 becomes law, the long-term savings would dwarf the short-term costs.

As a diabetes nurse educator and someone who manages diabetes every day, I can tell you that passing this bill will change the lives and improve the health of tens of thousands of low-income and senior Californians. AB 447 has bipartisan support, and if it reaches Gov. Jerry Browns desk, he should sign this lifesaving bill into law.

Read the original here:
Diabetes monitor bill will cut costs and save lives - Sacramento Bee

Of all the medical tests expectant mothers undergo in the months before childbirth, perhaps one of the most important evaluates for gestational diabetes. This pregnancy-related conditionin which hormonal changes cause blood sugar levels to rise dangerouslyis increasingly common, but moms-to-be can still take key steps to protect their health and that of their babies.

According to a 2016 report from the U.S. Centers for Disease Control and Prevention, as many as 9 percent of pregnant women are diagnosed with gestational diabetes. The condition used to be relatively uncommon, but the rate has risen dramatically in recent years.

To evaluate for gestational diabetes, women between the 24th and 28th week of pregnancy undergo a routine screening. This test is performed earlier in pregnancy if certain risk factors are present, inclusive of:

African-American, Native-American, Asian-American, Hispanic or Pacific Islander ethnicity

History of gestational diabetes

Presence of obesity

Prior delivery of a large infant (10 pounds or more)

History of stillbirth

Strong family history of diabetes

The test involves drinking a bottle of a glucose solution (called Glucola), and having blood drawn an hour later to analyze glucose levels. If a womans blood sugar is higher than 135 mg/dL, shes referred for whats called an oral glucose tolerance testa more stringent screening involving an overnight fast, consuming another glucose solution and having blood drawn four times over three hours. An abnormal result confirms the diagnosis of gestational diabetes.

Gestational diabetes risks to mother and baby

Why is it important to test blood sugar levels during pregnancy? Because when levels rise and remain chronically high, gestational diabetes poses particular risks to both mom and baby.

Associated risks to the mother include the following:

Miscarriage

Pregnancy complications such as preeclampsia, a condition involving seriously high blood pressure that can harm both mother and child

Premature delivery, particularly if gestational diabetes is diagnosed before 24 weeks gestation

Delivering an overweight baby (more than 10 pounds), which raises the risk of requiring a cesarean birth

Associated risks to the baby include the following:

Fetal death caused by the excessively high sugar levels in the mothers blood

Birth-related injuries caused by larger size

Low blood sugar and electrolyte abnormalities in the neonate after birth

Premature birth

Temporary respiratory problems in the newborn

Jaundice or yellowing of the skin, which resolves with treatment

Unfortunately, not all risks to mom and baby from gestational diabetes disappear after childbirth. Half or more of women diagnosed with the condition during pregnancy will eventually develop type 2 diabetes. Research shows that children of women with gestational diabetes are at higher risks of developing type 2 diabetes.

Tips to control gestational diabetes

If you or a loved one has been diagnosed with gestational diabetes, theres a lot that can be done to protect both moms and babys health despite the condition. Some cases can be managed without prescribing insulin. Implementation of regular exercise and dietary changes can effect good glucose control. Eating fewer sweets and smaller, more frequent meals can greatly affect blood sugar levels for the better.

Checking blood sugars regularly is an important tactic to ensure levels stay stable. Additionally, its important that you bring your sugar log to each prenatal visit, so your health provider can monitor your progress. If insulin is recommended by your doctor, make sure you take it as prescribed.

Kecia Gaither, M.D., MPH, FACOG, a perinatal consultant and womens health expert, is a double board-certified physician in OB/GYN and Maternal-Fetal Medicine in New York City. http://www.keciagaither.com

Read this article:
Gestational diabetes: Tips for a healthy mom and baby - Amsterdam News

Fredonia alumni Nick Catanzaro, 13, with Dr. Deborah Good, 87, at Virginia Tech, having fun celebrating last falls #FREDlanthropy Day.

A Fredonia alumnus, now a graduate student at Virginia Tech, has been awarded a fellowship to investigate a virus responsible for significant economic losses in the swine industry.

Nicholas Catanzaro, of Lewiston, N.Y., completed a bachelors degree in Molecular Genetics at Fredonia in 2013. He first visited Virginia Tech during the summer of 2012 to participate in Research Experiences for Undergraduates, a 10-week summer program that introduced him to microbiology research at the university.

Mr. Catanzaro credited his undergraduate professors at Fredonia with preparing him for the next step in his studies. Through integrative and engaging experiences in both the classroom and lab, I learned valuable skills and techniques that allowed me to hit the ground running upon starting my dissertation research, Catanzaro said. However, it was the environment and culture at Fredonia, especially within the Biology department, that prepared me the most. The people around me, both my peers and professors, made science exciting and motivated me to learn.

Catanzaro, a Ph.D. student in the Virginia Tech Department of Biomedical Sciences and Pathobiology, hopes his research on porcine reproductive and respiratory syndrome virus (PRRSV) will eventually help scientists develop safer, better vaccines. He was recently awarded a two-year, $95,000 fellowship from the U.S. Department of Agricultures National Institute of Food and Agriculture for his research.

This is one of the most economically devastating global swine pathogens and causes more than $600 million in economic losses in the United States alone each year, Catanzaro said. My fellowship looks at how the virus causes disease in pigs. Thats important because scientists are trying to make safer, more-effective vaccines for pigs against the virus.

First discovered in 1987, PRRSV causes reproductive failures in pregnant sows and respiratory disease in young piglets. Although it has similarities to the Coronaviridae family of viruses, which include the deadly severe acute respiratory syndrome (SARS), it cannot spread from animals to humans and poses no food safety threat.

Catanzaros interest in research peaked during his time at Fredonia, he said. During my junior and senior years at Fredonia, I worked on an undergraduate research project with Dr. Theodore Lee, Cantanzaro said. We were interested in microbial communities involved in a unique geological process along the banks of Canadaway Creek. This research experience allowed me to apply the skills and techniques discussed in the classroom to a real world problem. In working with Dr. Lee, I realized research was something I enjoyed and would like to pursue as a career.

Thanks to his Fredonia undergraduate degree, Catanzaro is able to do just that.

Reprinted in part with permission from Virginia Tech University.

The Northern Chautauqua Community Foundation is offering a Grant Writing Workshop on Oct. 10 from 9 to 11 a.m. This ...

SILVER CREEK Two sessions of the five-hour pre-licensing course will be offered by the Community Education ...

Oct. 19-22Unless otherwise noted, reservations for events may be made at: http://alumni.fredonia.edu/Events.aspx. ...

Originally posted here:
Science graduate helps to conquer a global problem - Evening Observer

TOM MULHOLLAND

Last updated05:00, August 20 2017

123RF

If I had a belief that vaccination was harmful, I wouldn't vaccinate my kids or myself.

Belief is an interesting thing. It is the cause of much of the conflict in the world, our communities, and in our own homes. It can seriously affect our wellbeing. Current conflict of beliefs sees war, fatal riots in the US, and political resignations and resurrections in our own land.

Beliefs are layered down and they become more deeply entrenched through a process known as the Ladder of Inference. Beliefs can cause actions or inactions, such as vaccinating or not vaccinating yourselves or your children.

For years, I believed vaccination was relatively safe and prevented terrible diseases. I vaccinated myself, my children and thousands of patients in my medical practices. The belief was based on what I had learnt in getting a FirstClass Honours degree in molecular genetics, a further five years of study to get my medical degree then about 10 years' clinical experience as a doctor.

READ MORE:*Dr Cathy Stephenson: Vaccinations are part of a 'bigger picture'*Vaxxed: A view from both sides of the debate*To frame anti-vaccine rhetoric as 'debate' is dangerous and wrong

So, my belief was seriously challenged with news that vaccination could potentially be linked to autism. I felt sick. I couldn't sleep. I became a doctor to help people, not harm them, myself or my own children. Contrary to some beliefs, we don't become doctors to work for pharmaceutical companies and we are not rewarded by them with perks and overseas travel.

So how could this be? I needed to know more what research was out there to suggest or prove a link with vaccination and autism. My enquiry over 10 years ago showed there was no link and in 2010 the original study was discredited and the author criticised for serious misconduct.

Proper studies of 500,000 Danish children, 27,000 Canadian children and Japanese children have shown no link with vaccination and autism. To my medical and scientific brain there is no link: vaccination is safe while not vaccinating is unsafe and dangerous. As I write this article, there are reports of vaccinations rates being below 60 per centin some areas, and diseases like polio are making a return.

If I had a belief that vaccination was harmful, I wouldn't vaccinate my kids or myself. Whilewriting this article I did a Google search on vaccination and autism. One site listed a number of scientific papers supporting the argument. Now, reading scientific papers is hard work even for someone who has spent their life doing so. The terms and names of compounds and cellular processes are confusing and hard to make sense of. But whatI could make sense of, was that the articles had nothing to do with vaccination and autism together but definitions of cellular pathways unrelated to either entity.

So, this strengthens thebelief that, as a scientist, as a father and as a doctor, vaccination is not only safe, but vital for our health and wellbeing, both as individuals and as communities.

My belief is also that we should debate the issue not the characters of the people who have conflicting beliefs. Some people have a belief in a sentinel being in the sky, in a god or gods they have never seen. To try and argue otherwise can be frustrating for both sides. If their beliefs don't create actions that impede others wellbeing, they are both entitled to them.

It's when a belief causes harm to others and especially unprotected infants who don't yet have beliefs that the debate can get heated.

The key is education without judgement. In simple terms, play the ball and not the individual, understand their beliefs and re-examine your own, whatever they may be.

Dr Tom Mulholland is an Emergency Department doctor and GP with more than 25 years' experience in New Zealand. He's currently on a mission, tackling health missions around the world.

-Stuff

Read more from the original source:
Dr Tom: Why I believe in vaccinations - Stuff.co.nz

Molecular diagnostics and personalized medicine major Myriad Genetics, Inc. (MYGN - Free Report) achieved another milestone as its EndoPredict test got positive coverage decision from Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies.

Notably, EndoPredict is Myriad Genetics next-generation, multigene prognostic test for breast cancer.The test provides information to help doctors devise personalized treatment plans.

Following the full implementation of these decisions, Myriad Genetics will have coverage for over 90% of breast cancer patients post implementation of these decisions.

Considering that EndoPredict has been used clinically in more than 15,000 patients, we areconfident about the growing adaptability of this test post the Medicare coverage approval.

As per a report provided by GBI Research, the global breast cancer treatment market will reach a worth of $17.2 billion by 2021, at a CAGR of 7.3%. Thus, the company clearly has bountiful prospects in this market.

Also, we note that the company has recently received extended Medicare coverage for its Prolasis test.

In this regard we note that, for the past three months, Myriad Genetics has been trading above the broader industry. The stock has gained 32.2%, higher than the industrys gain of 4.5%.

Recent Developments

Myriad Genetics announced that its BRACAnalysis CDxcompanion diagnostic test successfully identifiedBRCA-mutated patients with HER2- metastatic breast cancer in the OlympiAD trial who responded better to treatment with olaparib than standard chemotherapy.

Also, Myriad Genetics presented favorable findings from its BRACAnalysis CDx test which successfully identified patients with metastatic breast cancer in Phase 3 OlympiAD Study.

Zacks Rank & Key Picks

Myriad Genetics carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are IDEXX Laboratories, Inc. (IDXX - Free Report), Lantheus Holdings, Inc. (LNTH - Free Report) and Align Technology, Inc. (ALGN - Free Report). Align Technology sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank #2 (Buy). You canseethe complete list of todays Zacks #1 Rank stocks here.

Align Technology has a long-term expected earnings growth rate of 26.6%. The stock has rallied roughly 22.3% over the last three months.

Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 70.4% over the last six months.

IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained around 6.8% over the last six months.

4 Surprising Tech Stocks to Keep an Eye on

Tech stocks have been a major force behind the markets record highs, but picking the best ones to buy can be tough. Theres a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now before the next wave of innovations really takes off.

See Stocks Now>>

Read more:
Myriad Genetics' EndoPredict Gets Positive Coverage Decision - Zacks.com

WASHINGTON, DC--(Marketwired - Aug 18, 2017) - The Alliance for Regenerative Medicine (ARM) released today its most recent quarterly data report, offering an in-depth look at cell therapy, gene therapy, tissue engineering and broader global regenerative medicine sector trends and metrics in the second quarter and first half of 2017.

Using information provided by ARM's data partner Informa, the quarterly data report details industry-specific statistics compiled from more than 822 cell therapy, gene therapy, tissue engineering and other regenerative medicine companies worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events and current legislative and regulatory priorities.

The Q2 2017 data report also features expert perspectives from ARM member representatives and other key stakeholders, highlighting important focus areas for the sector:

Expert perspective on the growing interest and advantages of induced pluripotent stem cells as a therapeutic platform, with insights from:

Addressing the unique aspects of market access and reimbursement policy for cell and gene therapies, with insights from:

"At mid-point 2017, this sector has nearly or actually surpassed 2016 year-end totals by several metrics, signifying a renewed uptick in dealmaking and partnering activity across the sector," said Janet Lynch Lambert, ARM's Chief Executive Officer. "We are looking forward to an eventful second half of the year, with several anticipated high-profile product approvals and additional clinical progress in several key therapeutic areas."

Highlighted findings from the Q2 2017 data report include:

ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial information, clinical trial numbers and clinical data events.

The report is available online here. For more information, please visit http://www.alliancerm.org or contact Lyndsey Scull at lscull@alliancerm.org.

About The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 270 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org

Go here to read the rest:
The Alliance for Regenerative Medicine Releases Q2 2017 Data ... - Benzinga

ISSCA 5TH INTERNATIONAL SYMPOSIUM TO TAKE PLACE AT THE HOTEL SOFITEL IN RABAC THIS SEPTEMBER 30

Global Stem Cells Group, a global network of practitioners, doctors, researchers, and medical advocates that work in tandem to advance the study of regenerative medicine and stem cell development in our world today, this week, through their Stem Cell Conference subsidiary branch, officially announced their International Society for Stem Cells Application (ISSCA) 5th International Regenerative Medicine Symposium will officially take place at the Hotel Sofitel in Rabac.

Occurring this September 30, 2017, the symposium stands to bring together the industrys leading thinkers and doctors for days of collaboration.

To complement the hosting of the symposium, Global Stem Cells Group also announced a scientific program with three different modules that will be made available to event attendees.

We are constantly developing new events, programs, and educational opportunities that provide doctors and students with the ability to learn about regenerative medicine in a live and supportive environment, said Dr. Benito Novas, Founder and Owner of Global Stem Cells Group. We are incredibly excited to be hosting our symposium at the Hotel Sofitel, and we look forward to administering our scientific program to all who are interested.

Module 1, Biologic and Molecular basis for Regenerative Medicine, includes cellular culture and expansion, therapeutic potential, bioactive agents, plus much more. Module 2, Therapeutic Applications: Adult Stem Cells from Bench to Bedside, goes through regenerative orthopedics, protocols, and clinical experiences for students. Lastly, Module 3, Regulations, Marketing and Global Overview of the Stem Cell Industry, is a U.S. Research Policy and Stem Cells overview of the FDA regulatory process today.

To learn more about the program, visit http://www.stemcellgroup.org.

To learn more about the event, visit: http://www.stemcellconference.org.

About Global Stem Cells Group

Read more from the original source:
International Regenerative Medicine Symposium will officially take place in Rabat, Morocco - PRUnderground (press release)

SAN FRANCISCO, CA--(Marketwired - August 18, 2017) - In an update on this company's clinical cell therapy programs targeting blood cancers and osteoarthritis in the knee, Gabrielle Zhou of Maxim Group describes progress that sets the stage for "value inflection."

Included in this article is: Cellular Biomedicine Group Inc.'s(NASDAQ: CBMG)

Zhou summed up Cellular Biomedicine Group Inc.'s recent activities in an Aug. 9 research report. "CBMG's cell therapy programs continue to make progress," she wrote. "We expect to see data from both the CARD-1 and CALL-1 chimeric antigen receptor T-cell (CAR-T) studies by 2017E, setting the stage for a value inflection as CBMG becomes a Phase 2 CAR-T player."

The analyst also noted the company has enough cash to get to that stage. "CBMG ended the period with $27M in cash," Zhou noted. "At the current burn rate, we estimate CBMG has sufficient capital to fund through topline data releases (by 2017E) from its CARD-1 and CALL-1 studies, which should represent catalysts for the stock."

Continue reading this article:'Keep a Close Eye On' This Regenerative Medicine Firm

About Streetwise Reports -- The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

DISCLOSURES:

The following company mentioned in this article is a billboard sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. Cellular Biomedicine Group Inc. paid Streetwise Reports to distribute this press release on its behalf. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.

Please see the end of the article for the complete disclosures: 'Keep a Close Eye On' This Regenerative Medicine Firm

See more here:
Streetwise Reports Examines One Regenerative Medicine Firm to ... - Markets Insider

NEW YORK, Aug. 16, 2017 /PRNewswire/ -- "Global collagen & gelatin market for regenerative medicine projected to grow at a CAGR of 10.1% and 7.8% respectively."

The global collagen market for regenerative medicine is projected to grow from USD 420.6 million in 2017 to USD 679.9 million by 2022, at a CAGR of 10.1% during the forecast period.

Read the full report: http://www.reportlinker.com/p05064743/Collagen-Gelatin-Market-for-Regenerative-Medicine-by-Source-Bovine-Porcine-Marine-Application-Wound-Care-Orthopedic-Cardiovascular-Value-and-Volume-Analysis-Global-Forecast-to.html

The global gelatin market for regenerative medicine is projected to grow from USD 65.2 million in 2017 to USD 94.9 million by 2022, at a CAGR of 7.8% during the forecast period. The key factors propelling the growth of the global collagen and gelatin market for regenerative medicine include rising prevalence of chronic diseases, rapid growth in aging population, and growing government & private funding to support the development of regenerative medicine. However, the availability of alternative biomaterials for regenerative medicine is expected to restrain the growth of this market.

"The marine collagen segment is expected to grow at the highest CAGR in the global collagen market for regenerative medicine." On the basis of source, the global collagen market for regenerative medicine has been classified into bovine collagen, porcine collagen, marine collagen, and other sources. In 2017, the bovine collagen segment is expected to command the largest share of the global collagen market for regenerative medicine. However, owing to advantages, such as low immunogenicity and high biocompatibility the marine collagen segment is projected to grow at the highest CAGR during the forecast period.

"The orthopedic segment is expected to grow at the highest CAGR in the global collagen market for regenerative medicine." On the basis of application, the global collagen market for regenerative medicine has been segmented into orthopedic, wound care, cardiovascular, and other applications. In 2017, the orthopedic applications segment is expected to command the largest share of the global collagen market for regenerative medicine. However, owing to factors such as rising prevalence of chronic wounds, the wound care segment is projected to register the highest CAGR during the forecast period.

"Asia-Pacific to witness the highest growth during the forecast period." North America held the largest share of the collagen market for regenerative medicine and gelatin market for regenerative medicine, while Asia-Pacific is expected to witness the highest growth during 2017 to 2022 in both the markets.

The high growth in the collagen market for regenerative medicine can primarily be attributed to the large number of CVD patients and diabetics with DFU (diabetic foot ulcers) in the region, increasing number of research studies, and increasing focus of industry players on emerging APAC countries. Similarly, the large number of patients suffering from skin burns & brain tumors and increasing number of research studies in the region are the major factors driving the growth of the APAC market.

Break of primary participants was as mentioned below: By Company Type Tier 145%, Tier 240% and Tier 315% By Designation C-level41%, Director Level30%, Others29% By Region North America38%, Europe31%, Asia-Pacific19%, RoW12%

The major players operating in the global collagen market for regenerative medicine include Integra LifeSciences Holding Corporation (U.S.), Collagen Matrix, Inc. (U.S.), Collagen Solutions plc (U.K.), Royal DSM (Netherlands), Vornia Biomaterials, Ltd. (Ireland), SYMATESE (France), and NuCollagen, LLC. (U.S.). Similarly, the major players operating in the global gelatin market for regenerative medicine include GELITA AG (Germany), Nitta Gelatin, Inc. (Japan), and PB Gelatin (Belgium).

Research Coverage: The report analyzes the global collagen and gelatin market for regenerative medicine and aims at estimating market size and future growth potential of this market based on various segments such as source, application, and region. The report also includes an in-depth regulatory analysis for various regions across the globe and competitive analysis of the key players in this market along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned four strategies.

This report provides insights on the following pointers: Market Penetration: Comprehensive information on product portfolios offered by the top players in the global collagen and gelatin market for regenerative medicine. The report analyzes the global collagen and gelatin market for regenerative medicine by source, application, and region Market Development: Comprehensive information about lucrative emerging markets the report analyzes the markets for collagens and gelatins for regenerative medicine across various regions Market Diversification: Exhaustive information about new services or service enhancements, growing geographies, recent developments, and investments in the global collagen and gelatin market for regenerative medicine Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the global collagen and gelatin market for regenerative medicine

Read the full report: http://www.reportlinker.com/p05064743/Collagen-Gelatin-Market-for-Regenerative-Medicine-by-Source-Bovine-Porcine-Marine-Application-Wound-Care-Orthopedic-Cardiovascular-Value-and-Volume-Analysis-Global-Forecast-to.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/collagen--gelatin-market-for-regenerative-medicine-by-source-bovine-porcine-marine-application-wound-care-orthopedic-cardiovascular-value-and-volume-analysis---global-forecast-to-2022-300505537.html

Continued here:
Collagen & Gelatin Market for Regenerative Medicine (by Source ... - PR Newswire (press release)

The global collagen market for regenerative medicine is projected to grow from USD 420.6 Million in 2017 to USD 679.9 Million by 2022, at a CAGR of 10.1% during the forecast period.

The global gelatin market for regenerative medicine is projected to grow from USD 65.2 Million in 2017 to USD 94.9 Million by 2022, at a CAGR of 7.8% during the forecast period. The key factors propelling the growth of the global collagen and gelatin market for regenerative medicine include rising prevalence of chronic diseases, rapid growth in aging population, and growing government & private funding to support the development of regenerative medicine.

The report analyzes the global collagen & gelatin market for regenerative medicine by source, application, and region. On the basis of source, the global collagen market for regenerative medicine has been segmented into bovine collagen, porcine collagen, marine collagen, and other sources. In 2017, the bovine collagen segment is expected to command the largest share of the global collagen market for regenerative medicine. The large share of this segment is attributed to the lower cost and extensive availability of bovine collagen.

Similarly, on the basis of source, the global gelatin market for regenerative medicine has been segmented into bovine gelatin, porcine gelatin, and gelatin from other sources. In 2017, the bovine gelatin segment is expected to command the largest share of the global gelatin market for regenerative medicine. Owing to its extensive availability, this segment is also projected to register the highest CAGR during the forecast period.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Collagen Market for Regenerative Medicine, By Source

7 Gelatin Market for Regenerative Medicine, By Source

8 Collagen Market for Regenerative Medicine, By Application

9 Gelatin Market for Regenerative Medicine, By Application

10 Collagen Market for Regenerative Medicine, By Region

11 Gelatin Market for Regenerative Medicine, By Region

12 Competitive Landscape

13 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/jrw4ql/collagen_and

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/7748-million-collagen--gelatin-market-for-regenerative-medicine-2017---global-forecast-to-2022-300505917.html

SOURCE Research and Markets

http://www.researchandmarkets.com

The rest is here:
$774.8 Million Collagen & Gelatin Market for Regenerative Medicine ... - PR Newswire (press release)

Published time: 18 Aug, 2017 16:05

Oxford University scientists have found a ground-breaking way of 3D-printing living tissue that could pave the way for regenerative medicine.

The new way to 3D-print stem cells to recreate complex living tissues was devised by Oxford scientists in collaboration with Bristols School of Cellular and Molecular Medicine.

Read more

The discovery could revolutionize regenerative medicine as it allows for the reproduction of complex tissue that could replace or repair damaged or severed areas of the body.

The versatility and robust nature of our approach provides a new set of tools for bottom-up tissue engineering at a low cost, researchers claim in their paper, published in Scientific Reports.

One of the main hurdles of 3D-printing organic matter has been that cells move within the printed structures, and the soft scaffoldings supporting them tend to collapse on themselves.

The new method could see the production of tissue in self-contained cells that support the structures and could help them keep their shape.

We were aiming to fabricate 3D living tissues that could display the basic behaviors and physiology found in natural organisms, said Alexander Graham, lead author and 3D Bioprinting Scientist at OxSyBio (Oxford Synthetic Biology).

The research team wanted to produce prints with the same cell complexity of native tissue.

Read more

To date, there are limited examples of printed tissues, which have the complex cellular architecture of native tissues.

Hence, we focused on designing a high-resolution cell printing platform, from relatively inexpensive components, that could be used to reproducibly produce artificial tissues with appropriate complexity from a range of cells including stem cells.

The new method seems to improve the survival rate of cells, as they had a high viability average of 90 percent.

The bioprinting approach developed with Oxford University is very exciting, as the cellular constructs can be printed efficiently at extremely high resolution with very little waste, said Adam Perriman, of the University of Bristols School of Cellular and Molecular Medicine.

The researchers believe the approach could put a halt to animal testing and play a key role in drug and toxin screening.

There are many potential applications for bioprinting and we believe it will be possible to create personalized treatments by using cells sourced from patients to mimic or enhance natural tissue function, said Sam Olof, chief technology officer at OxSyBio.

View original post here:
Scientists 3D-print 'high-resolution' living tissue RT UK - RT.com - RT

Eddie Izzard is to appear in a 50-seater venue at the Edinburgh Fringe on Saturday August 19.

Izzard is taking part in a run of gigs featuring comedy promoter Stephen Garland, who runs comedy gigs in Spain. Garland is telling his story onstage of being diagnosed with PPMS and raising money to get to Russia to stop his disease with Stem Cell Therapy. More info atwww.stopmyppms.com

The show title -'The Pre-Disposed'- came about as a correction by a Psychologist that it is politically incorrect to refer to PPMS, despite its 'No Treatment, No Cure' reality as a 'Terminal Disease'.Which I had done and was informed that I should use the more PC term, a Pre-Disposed illness, explains Garland.

Each evening Garland will bejoined by a different comedian. Many of them are featured in Garland's story. The idea is to bring promoter and comedians together to discuss in terms of comedy whether 'the comic' is somehow pre-disposed to perform and can it be what defines the comedy style that the public love so much.

This list of comics represents for me some of the coalface of Fringe innovation and I am truly honoured that they will join my humble amateurish performance, says Stephen.

Fans will need to go to tonight's gig (August 18) to find out how to get tickets for Izzard's appearance.

WHERE: Venue 156 Banshee Labyrinth ~ Banqueting Hall

WHEN: August 12 - 19 inclusive

TIME: 21:50

TICKETS: FREE - followed by a bucket with all proceeds going towww.stopmyppms.com

Aug 15 | TueCarey Marx- (ENG) - Fringe Show - The Afterwife -https://tickets.edfringe.com/whats-on/carey-marx-the-afterwife

Another fringe favourite and loved in festivals across the planet, constant innovator who each year brings something extraordinary to Edinburgh.

Aug 16 | Wed -Simon Munnery- (ENG) - Fringe Show - Simon Munnery: Renegade Plumber -https://tickets.edfringe.com/whats-on/simon-munnery-renegade-plumber

A legend of alternative comedy and coming to the Fringe weaving his surreal comedy brilliance in Edinburgh since before anyone can remember.

Aug 17 | Thu -Alexis Dubus- (ENG) - Fringe Show - Marcel Luconts Whine List -https://tickets.edfringe.com/whats-on/marcel-lucont-s-whine-list

One of the finest comedians whether as himself or his internationally award winning comedy creation Marcel Lucont. Alexis is a festival favourite loved from New Zealand to Barcelona.

Aug 18 | Fri -Trevor Lock- (ENG) - Fringe Show - Trevor locks Community Circle -https://tickets.edfringe.com/whats-on/trevor-lock-s-community-circle

Trevor has a totally unique style built on sheer charm that makes his largely 'joke free' Community Circle an unmissable comedy event that has wooed fans across the world. Trevor was instrumental in bringing a professional gravitas to a very fledgling comedy scene in Rio through 2016. Already packing a 5 star review from Scotsman!!!

Aug 19 | Sat -EDDIE IZZARD.

See the original post here:
News: Eddie Izzard To Appear At Intimate Fringe Benefit - Beyond The Joke

The human joint is a wonderfully flexible and durable evolutionary innovation, but like any good machine eventually itwears down. And in many people, this wearing is thought to causearthritis.

Pain from arthritis strikes some 54.4 million U.S. adults, and is "one of the most common chronic conditions in the nation," accordingto theCenters for Disease Controlwebsite. The disease causes stiffness, swelling and pain in the joints and has been found in humans for thousands of years. (Scientists even identified evidence of arthritis inNefertari's mummified knees.) But researchers havelong assumed that arthritis rates have spiked in recent years as people live longer and populations grow heavier. Now, as Mitch Leslie reports forScience,a study of ancient knees has finally provided evidence to support the trend, and suggests that arthritis maynot be an inevitable fate ofold age.

To tease out the history of arthritis, Harvard University biologist Ian Wallace studied skeletons of middle-aged and elderly people from various time periods of America, including specimens from Native Americansup to 6,000 years old. He thought that perhaps in the early days of humanitywhen when walking was the main way to get around and many people spent their lives hunting, farming or fightingthe rates of arthritis would actually be fairly high due to the joint stress fromall this activity.

But this wasn't the case.

Instead, it appears that osteoarthritis of the knees affects far more Americans today than even just a few decades ago, Leslie reports. And aftercontrolling for weight and age, the results suggest that these factors have no effect on how many people develop the disorder. Strikingly, the rate of osteoarthritis has more than doubled among Americans just since 1940. Wallace and his team pubished their results earlier this month in the journal Proceedings of the National Academy of Sciences.

We were able to show, for the first time, that this pervasive cause of pain is actually twice as common today than even in the recent past," Wallace says in a statement. "But the even bigger surprise is that its not just because people are living longer or getting fatter, but for other reasons likely related to our modern environments.

The study doesn't make any conclusions for why this spike has occurred, but study co-author Daniel Lieberman suggests that the epidemic of sitting in mondern-day Americacould be affecting how our joints are formed and maintained, leading to more arthritis,Richard Harris reports for NPR. Changing diets and the rising rates of injuries from sports among children and adults could also play a role.

Though cause is still unknown, the study's results suggest that the disease may not be as inevitable as once believed. We should think of this as a partly preventable disease,"Lieberman says in a statement.

Today, there is no true "cure" for arthritis, only management of pain, such as takingmedications, wearing splintsand losing weight. In 2003, Americans spent some $80.8billion on diagnosis and treatment of the disease. But researchers hope to eventually stem the flow of that money. The latest study gives hope that with continued testing of treatments and ways to prevent osteoarthritis, we can eventually beat this ancient ailment.

Like this article?SIGN UP for our newsletter

Go here to read the rest:
What a 6000-Year-Old Knee Can Teach Us About Arthritis - Smithsonian

Over time, rheumatoid arthritis can damage the joints themselves as well as the nearby cartilage.

There is no cure for the condition, however the symptoms can be treated using medication and supportive therapies such as physiotherapy.

In this large population-based study, we were able to address these questions more thoroughly than has been possible before, the researchers wrote.

Using the Pill for more than seven years - the average length of use among the study participants - was associated with a 19 per cent lower risk of developing arthritis.

Further research is required to explore the biological mechanisms behind our findings.

The oral contraceptive pill contains artificial versions of the female hormones oestrogen and progesterone, which women produce naturally to prevent the ovary releasing an egg.

Pill usage declines steeply with age, from two-thirds of women aged 20 to 24, to 11 per cent of women in their late 40s.

There is no upper age limit beyond which healthy women should not take the pill, however those who smoke are advised not to take it above 35, according to the Family Planning Association, a sexual health charity.

Published in the Annals of Rheumatic Diseases, the study also sought to identify whether breastfeeding was associated with a lower risk of arthritis, as had been suspected, however no significant link was found.

Continued here:
Does the pill prevent arthritis? New study suggests a link - Telegraph.co.uk

Sacramento Bee

A 14-foot-tall arthritis patient receives treatment at the Sacramento Zoo Sacramento Bee At 14 feet tall and nearly 1,600 pounds, Goody is an unusual arthritis patient. She's also a reticulated giraffe, and a celebrity of sorts at the Sacramento Zoo. In addition to the attention and treats she gets from zoo visitors at the feeding deck of ...

Link:
A 14-foot-tall arthritis patient receives treatment at the Sacramento Zoo - Sacramento Bee

Saturday August 19, 2017

A new study has revealed that the prevalence of osteoarthritis in the knees of humans has doubled since the mid-20th century - and not because we're living longer.

Dr. Ian Wallace, a postdoctoral research fellow in the Department of Human Evolutionary Biology at Harvard University, studied over 2000 skeletons from three different time periods in order to reach that conclusion. He looked at 176 prehistoric skeletons, and many more from both the early industrial era and the post-industrial era, which included specimens from the early 2000's. Modern specimens were more likely to have knee arthritis than either group of older skeletons.

What was really surprising was that Dr. Wallace found that the increase in arthritis was there even if he controlled for the fact that we're living longer, and the general increase in obesity in modern times, which is a risk factor for osteoarthritis. Dr. Wallace thinks the most obvious candidate to explain the increase in knee osteoarthritis is the moderndecline in physical activity. This also means that osteoarthritis may be more preventable than previously thought.

See the article here:
Quirks & Quarks - CBC.ca